Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss, known as Androgenetic Alopecia, is often caused by hormones and can be diagnosed using noninvasive techniques. Treatments include topical minoxidil and oral finasteride, with new treatments being explored. There may also be a link between this type of hair loss and heart disease risk.

Finasteride can have lasting negative effects on brain function and behavior by disrupting neurosteroid production.

Removing a testicular tumor in a dog reduced its aggressive behavior and skin problems.

A man with a rare adrenal cancer showed unusual symptoms and died four months after diagnosis.

17α-estradiol is a safe estrogen that might protect the brain and doesn't cause feminization, needing more research for treating brain diseases.

Transgender and nonbinary individuals experience hair loss, with transmen on testosterone seeing more severe hair loss, while feminizing hormones may stabilize hair loss in transwomen.

Feminizing hormone therapy increases kidney filtration rate.

Cyproterone acetate is a safe treatment that causes mild feminizing effects in adolescent trans-girls.

Gender-affirming hormone therapy changes hair growth in transgender people, with feminizing therapy reducing hair and masculinizing therapy increasing it, but sometimes additional treatment is needed.

Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.

Hormone therapy may increase migraines in transgender women and decrease them in transgender men; more research is needed on migraine management in transgender individuals.

The document concludes that respectful, gender-affirming healthcare improves mental health and encourages continued medical care for transgender and non-binary individuals.

Three siblings with a rare genetic condition had abnormal sexual development and chose different gender identities, needing surgery and therapy.

Transgender patients on masculinizing hormones have higher hair loss rates than cisgender women.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

Understanding how androgens work is key for creating new treatments for prostate issues and hair/skin conditions.

Androstenedione, a hormone supplement, doesn't improve muscle or performance and can cause harmful side effects.

Antiandrogens block male hormones and are not safe during pregnancy.

Cyproterone acetate is a safe treatment that causes modest feminization in transgender female adolescents, and works better with added estrogens.

Hormone therapy is essential for transgender individuals but requires careful management due to possible metabolic effects.

Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.

Inclusive and affirming healthcare is essential for improving transgender individuals' quality of life and health.

Hair follicle biology advancements may lead to better hair growth disorder treatments.

The document concludes that non-binary individuals need compassionate support and recognition in healthcare, without being pathologized.

Creating stronger blockers for skin enzymes might lead to better treatment for conditions like acne and excessive hair growth.

Minoxidil and finasteride treat hair loss in men, while minoxidil treats hair loss in women.

Oestrogens are key for bone growth during puberty in both boys and girls.

ADSC-CM treatment improved hair density and thickness in women with hair loss, safely and effectively.

Hormonal treatments can help with acne, especially in women, by lowering androgen levels or blocking their effects.

Women with PCOS often have skin problems like excessive hair, acne, hair loss, and dark patches, which can be treated with hormonal and non-hormonal therapies.